| 1 |
Smecuol E, Hwang HJ, Sugai E, Corso L, Chernavsky AC, Bellavite FP, et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J Clin Gastroenterol 2013;47:139-47.
DOI
|
| 2 |
Orlando A, Linsalata M, Notarnicola M, Tutino V, Russo F. Lactobacillus GG restoration of the gliadin induced epithelial barrier disruption: the role of cellular polyamines. BMC Microbiol 2014;14:19.
DOI
|
| 3 |
De Angelis M, Rizzello CG, Fasano A, Clemente MG, De Simone C, Silano M, et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue. Biochim Biophys Acta 2006;1762:80-93.
DOI
|
| 4 |
Harnett J, Myers SP, Rolfe M. Probiotics and the microbiome in celiac disease: a randomised controlled trial. Evid Based Complement Alternat Med 2016;2016:9048574.
|
| 5 |
Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, et al. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Gastroenterol 2019;53:e117-25.
DOI
|
| 6 |
De Palma G, Cinova J, Stepankova R, Tuckova L, Sanz Y. Pivotal advance: bifidobacteria and Gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease. J Leukoc Biol 2010;87:765-78.
DOI
|
| 7 |
Vriezinga SL, Auricchio R, Bravi E, Castillejo G, Chmielewska A, Crespo Escobar P, et al. Randomized feeding intervention in infants at high risk for celiac disease. N Engl J Med 2014;371:1304-15.
DOI
|
| 8 |
Borrelli M, Maglio M, Korponay-Szabo IR, Vass V, Mearin ML, Meijer C, et al. Intestinal anti-transglutaminase 2 immunoglobulin A deposits in children at risk for coeliac disease (CD): data from the PreventCD study. Clin Exp Immunol 2018;191:311-7.
DOI
|
| 9 |
Kho ZY, Lal SK. The human gut microbiome - a potential controller of wellness and disease. Front Microbiol 2018;9:1835.
DOI
|
| 10 |
Veeraraghavan G, Leffler DA, Kaswala DH, Mukherjee R. Celiac disease 2015 update: new therapies. Expert Rev Gastroenterol Hepatol 2015;9:913-27.
DOI
|
| 11 |
Losurdo G, Principi M, Iannone A, Ierardi E, Di Leo A. The interaction between celiac disease and intestinal microbiota. J Clin Gastroenterol 2016;50(Suppl 2):145-7.
|
| 12 |
Marasco G, Di Biase AR, Schiumerini R, Eusebi LH, Iughetti L, Ravaioli F, et al. Gut microbiota and celiac disease. Dig Dis Sci 2016;61:1461-72.
DOI
|
| 13 |
Girbovan A, Sur G, Samasca G, Lupan I. Dysbiosis a risk factor for celiac disease. Med Microbiol Immunol 2017;206:83-91.
DOI
|
| 14 |
Cenit MC, Olivares M, Codoner-Franch P, Sanz Y. Intestinal microbiota and celiac disease: cause, consequence or co-evolution? Nutrients 2015;7:6900-23.
DOI
|
| 15 |
Galipeau HJ, McCarville JL, Huebener S, Litwin O, Meisel M, Jabri B, et al. Intestinal microbiota modulates gluten-induced immunopathology in humanized mice. Am J Pathol 2015;185:2969-82.
DOI
|
| 16 |
Guandalini S, Assiri A. Celiac disease: a review. JAMA Pediatr 2014;168:272-8.
DOI
|
| 17 |
Lindfors K, Blomqvist T, Juuti-Uusitalo K, Stenman S, Venalainen J, Maki M, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol 2008;152:552-8.
DOI
|
| 18 |
Iannitti T, Palmieri B. Therapeutical use of probiotic formulations in clinical practice. Clin Nutr 2010;29:701-25.
DOI
|
| 19 |
Gagliardi A, Totino V, Cacciotti F, Iebba V, Neroni B, Bonfiglio G, et al. Rebuilding the gut microbiota ecosystem. Int J Environ Res Public Health 2018;15:1679.
DOI
|
| 20 |
Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, et al.ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136-60.
DOI
|
| 21 |
Silvester JA, Kurada S, Szwajcer A, Kelly CP, Leffler DA, Duerksen DR. Tests for serum transglutaminase and endomysial antibodies do not detect most patients with celiac disease and persistent villous atrophy on gluten-free diets: a meta-analysis. Gastroenterology 2017;153:689-701.e1.
DOI
|
| 22 |
Di Sabatino A, Vanoli A, Giuffrida P, Luinetti O, Solcia E, Corazza GR. The function of tissue transglutaminase in celiac disease. Autoimmun Rev 2012;11:746-53.
DOI
|
| 23 |
Lindfors K, Maki M, Kaukinen K. Transglutaminase 2-targeted autoantibodies in celiac disease: pathogenetic players in addition to diagnostic tools? Autoimmun Rev 2010;9:744-9.
DOI
|
| 24 |
Kumar J, Kumar M, Pandey R, Chauhan NS. Physiopathology and management of gluten-induced celiac disease. J Food Sci 2017;82:270-7.
DOI
|
| 25 |
Husby S, Koletzko S, Korponay-Szabo I, Kurppa K, Mearin ML, Ribes-Koninckx C, et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition guidelines for diagnosing coeliac disease 2020. J Pediatr Gastroenterol Nutr 2020;70:141-56.
DOI
|
webmaster
